Evaluation of a New Formulation That Improves the Bioavailability and Food Effec...

연구 요약

Evaluation of a New Formulation That Improves the Bioavailability and Food Effect of Abiraterone: An Open-Label, Crossover, Randomized, Controlled, Phase I Clinical Trial.

Clinical pharmacology in drug development 학술지에 발표된 이 연구는 Yi M, Tu S, Cheng Z 외 연구팀이 수행하였습니다.

이 연구는 'Evaluation of a New Formulation That Improves the Bioavailability and Food Effect of Abiraterone: An Open-Label, Crossover, Randomized, Controlled, Phase I Clinical Trial.'에 대한 과학적 분석을 제공합니다.

핵심 내용

This first-in-human phase I trial evaluated RL001, a self-emulsifying soft-capsule abiraterone developed to overcome the low bioavailability and food sensitivity associated with the 1000-mg Zytiga tablet that is used with prednisone according to NCCN guidelines. Plasma concentrations were quantified by LC-MS/MS and modeled in Phoenix WinNonlin 8.1 and SAS; GeoMean confidence intervals compared pharmacokinetics. Against 1000-mg abiraterone acetate tablet, the 200 mg RL001 achieved abiraterone Cmax GMR >125% and AUC0-t, AUC0-∞ 80-125%, indicating higher bioavailability and enabling a lower therapeutic dose. The GMR of prednisone and its metabolite remained within 80%-125%, confirming no interaction. Fed/fasted exposure ratios stayed around 80% for AUC and <80% for Cmax, eliminating food spikes. Hyperbilirubinemia and hypertriglyceridemia were significantly less frequent. The abiraterone self-emulsifying soft capsule represents a safer and more convenient therapeutic option in the management of prostate cancer.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41549788)